Indonesian Firms Join with Chinese Firm To Supply Antibiotics
This article was originally published in PharmAsia News
Executive Summary
Kimia Farma and Indofarma of Indonesia have signed an agreement with CSPC of China to supply Indonesia with antibiotics. Kimia Farma Director M. Sjamsul Arifin said the firm entered the agreement to ensure the stability of supply and prices for the antibiotics in the face of an expected shortage in the country within the next year. By cooperating with the Chinese firm, he said, the firm was contributing to a government effort to maintain supplies of the medicine at stable prices. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.